RT Journal Article
SR Electronic
T1 Pre-existing Cardiovascular Disease in United States Population at High Risk for Severe COVID-19 Infection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.11.20089714
DO 10.1101/2020.05.11.20089714
A1 Qureshi, Adnan I.
A1 Huang, Wei
A1 Lobanova, Iryna
A1 Siddiq, Farhan
A1 Suri, M. Fareed K.
A1 Naqvi, S. Hasan
A1 French, Brandi R.
A1 Gomez, Camilo R.
YR 2020
UL http://medrxiv.org/content/early/2020/05/15/2020.05.11.20089714.abstract
AB Background and Purpose There is increasing recognition of a relatively high burden of pre-existing cardiovascular disease in Corona Virus Disease 2019 (COVID-19) infected patients. We determined the burden of pre-existing cardiovascular disease in persons residing in United States (US) who are at risk for severe COVID-19 infection.Methods Age (≥60 years), presence of chronic obstructive pulmonary disease, diabetes, mellitus, hypertension, and/or malignancy were used to identify persons at risk for admission to intensive care unit, or invasive ventilation, or death with COVID-19 infection. Persons were classified as low risk (no risk factors), moderate risk (1 risk factor), and high risk (two or more risk factors present) using nationally representative sample of US adults from National Health and Nutrition Examination Survey 2017-2018 survey.Results Among a total of 5856 participants, 2386 (40.7%) were considered low risk, 1325 (22.6%) moderate risk, and 2145 persons (36.6%) as high risk for severe COVID-19 infection. The proportion of patients who had pre-existing stroke increased from 0.6% to 10.5% in low risk patients to high risk patients (odds ratio [OR]19.9, 95% confidence interval [CI]11.6-34.3). The proportion of who had pre-existing myocardial infection (MI) increased from 0.4% to 10.4% in low risk patients to high risk patients (OR 30.6, 95% CI 15.7-59.8).Conclusions A large proportion of persons in US who are at risk for developing severe COVID-19 infection are expected to have pre-existing cardiovascular disease. Further studies need to identify whether targeted strategies towards cardiovascular diseases can reduce the mortality in COVID-19 infected patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was availableAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data is available through NHANES website